このページの翻訳は実験的なもので、現在開発中です。お待ちしております
AC Immune マネジメント
マネジメント 基準チェック /24
AC Immune'sの CEO はAndrea Pfeiferで、 Apr2003年に任命され、 の在任期間は 21.17年です。 の年間総報酬はCHF 2.65Mで、 21.8%給与と78.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.58%を直接所有しており、その価値は$ 9.88M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と6.2年です。
主要情報
Andrea Pfeifer
最高経営責任者
CHF 2.7m
報酬総額
| CEO給与比率 | 21.8% |
| CEO在任期間 | 21.4yrs |
| CEOの所有権 | 2.4% |
| 経営陣の平均在職期間 | 5.6yrs |
| 取締役会の平均在任期間 | 6.4yrs |
経営陣の近況
Recent updates
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
Jul 26AC Immune (NASDAQ:ACIU) Is In A Strong Position To Grow Its Business
Jun 15
Shareholders Will Probably Hold Off On Increasing AC Immune SA's (NASDAQ:ACIU) CEO Compensation For The Time Being
Jun 15AC Immune SA's (NASDAQ:ACIU) 50% Share Price Surge Not Quite Adding Up
May 24AC Immune SA (NASDAQ:ACIU) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Apr 05We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Mar 15Companies Like AC Immune (NASDAQ:ACIU) Are In A Position To Invest In Growth
Oct 06We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
Jun 03Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?
Nov 25AC Immune Non-GAAP EPS of -$0.23 in-line
Jul 28Here's Why We're Not Too Worried About AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Jul 06AC Immune (NASDAQ:ACIU) Is In A Good Position To Deliver On Growth Plans
Feb 03AC Immune soars 17% on encouraging polyclonal antibody response in non-human primates
Jun 02Is AC Immune (NASDAQ:ACIU) In A Good Position To Deliver On Growth Plans?
May 09AC Immune reports Q1 results; outlook
Apr 28How Much Of AC Immune SA (NASDAQ:ACIU) Do Institutions Own?
Feb 28Analysts Just Made A Sizeable Upgrade To Their AC Immune SA (NASDAQ:ACIU) Forecasts
Jan 24We're Hopeful That AC Immune (NASDAQ:ACIU) Will Use Its Cash Wisely
Jan 19
If You Had Bought AC Immune's (NASDAQ:ACIU) Shares Three Years Ago You Would Be Down 61%
Dec 15Need To Know: Analysts Are Much More Bullish On AC Immune SA (NASDAQ:ACIU) Revenues
Nov 19AC Immune EPS misses by CHF0.02, beats on revenue
Nov 13AC Immune and Wuxi Biologics boost development of TDP-43 antibodies
Nov 09AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
Oct 30CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CHF 61m |
| Mar 31 2024 | n/a | n/a | -CHF 55m |
| Dec 31 2023 | CHF 3m | CHF 578k | -CHF 54m |
| Sep 30 2023 | n/a | n/a | -CHF 68m |
| Jun 30 2023 | n/a | n/a | -CHF 67m |
| Mar 31 2023 | n/a | n/a | -CHF 69m |
| Dec 31 2022 | CHF 2m | CHF 558k | -CHF 71m |
| Sep 30 2022 | n/a | n/a | -CHF 73m |
| Jun 30 2022 | n/a | n/a | -CHF 76m |
| Mar 31 2022 | n/a | n/a | -CHF 75m |
| Dec 31 2021 | CHF 2m | CHF 530k | -CHF 73m |
| Sep 30 2021 | n/a | n/a | -CHF 71m |
| Jun 30 2021 | n/a | n/a | -CHF 74m |
| Mar 31 2021 | n/a | n/a | -CHF 71m |
| Dec 31 2020 | CHF 2m | CHF 520k | -CHF 62m |
| Sep 30 2020 | n/a | n/a | -CHF 62m |
| Jun 30 2020 | n/a | n/a | -CHF 25m |
| Mar 31 2020 | n/a | n/a | -CHF 26m |
| Dec 31 2019 | CHF 2m | CHF 510k | CHF 45m |
| Sep 30 2019 | n/a | n/a | CHF 50m |
| Jun 30 2019 | n/a | n/a | CHF 18m |
| Mar 31 2019 | n/a | n/a | CHF 24m |
| Dec 31 2018 | CHF 2m | CHF 455k | -CHF 51m |
| Sep 30 2018 | n/a | n/a | -CHF 32m |
| Jun 30 2018 | n/a | n/a | -CHF 27m |
| Mar 31 2018 | n/a | n/a | -CHF 29m |
| Dec 31 2017 | CHF 2m | CHF 404k | -CHF 26m |
報酬と市場: Andreaの 総報酬 ($USD 3.13M ) は、 US市場 ($USD 2.40M ) の同規模の企業の平均を上回っています。
報酬と収益: Andreaの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Andrea Pfeifer (67 yo)
21.4yrs
在職期間
CHF 2,650,000
報酬
Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 21.4yrs | CHF 2.65m | 2.45% CHF 9.1m | |
| CFO & VP of Finance | 2.4yrs | データなし | 0.013% CHF 47.3k | |
| Chief Technical Operations Officer | 5.6yrs | データなし | 0.025% CHF 91.9k | |
| Chief Administrative Officer | 9.2yrs | データなし | 0.32% CHF 1.2m | |
| Chief HR Officer | 2.4yrs | データなし | 0.020% CHF 75.5k | |
| Chief Scientific Officer | less than a year | データなし | 0.0032% CHF 11.9k | |
| Senior VP of Investor Relations & Corporate Communications | no data | データなし | データなし | |
| General Counsel | no data | データなし | データなし | |
| VP of U.S. Finance & Corporate Development | 2.4yrs | データなし | データなし | |
| Head of AD - SME | 14.7yrs | データなし | データなし | |
| Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer | 8.6yrs | データなし | データなし | |
| VP & Head of Clinical Development | no data | データなし | データなし |
5.6yrs
平均在職期間
54.5yo
平均年齢
経験豊富な経営陣: ACIUの経営陣は経験豊富で経験豊富です（平均在職期間は5.6年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 8.3yrs | CHF 2.65m | 2.45% CHF 9.1m | |
| Chairman of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Non-Executive Chairman | 6.4yrs | CHF 179.00k | 0.039% CHF 146.0k | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | CHF 5.00k | データなし | |
| Member of Scientific Advisory Board | no data | CHF 105.00k | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Vice Chair | 2.9yrs | CHF 163.00k | 0.0092% CHF 34.3k | |
| Head of Clinical Advisory Board | no data | データなし | データなし |
6.4yrs
平均在職期間
74.5yo
平均年齢
経験豊富なボード: ACIUの 取締役会 は 経験豊富 であると考えられます ( 6.2年の平均在任期間)。